References
  1. Cardinale F et al. Community-acquired pneumonia in children. Early Human Development 2013; S49–S52
  2. Sinaniotis CA. Viral pneumonia in children: incidence and aetiology. Paediatr Resp Rev 2004; 5:S197–S200
  3. Talal F and Thomson Anne H. et al. The burden of pneumonia in children in the developed world. Paediatric Respiratory Reviews 2005; 6;76-82
  4. Waites K, Talkington D: Mycoplasma pneumoniae and Its Role as a Human Pathogen. Clin Microbiol Rev 2004; 17:697-728
  5. Saegeman V, Proesmans M, Dumke R. Pediatr Management of macrolide-resistant Mycoplasma pneumoniae infection. Infect Dis J. 2012; 31(11):1210-1
  6. Harris M, Clark J et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax 2011; 66:ii1-ii23
  7. Okazaki N, Narita M, Yamada S et al. Characteristics of macrolide-resistant mycoplasma pneumoniae strains isolated from patients and induced with erythromycin in vitro. Microbiol Immunol. 2001; 45:617-620
  8. Xin D, Mi Z Han X et al. Molecular mechanisms of macrolide resistance in clinical isolates of mycoplasma pneumoniae from China. Antimicrob Agents Chemother 2009; 2158-2159
  9. Liu Y, Ye X, Zhang H et al. Antimicrobial susceptibility of mycoplasma pneumoniae isolates and molecular analysis on macrolide resistant strains from shanghai, China. Antimicrob Agents Chemother 2009; 53: 2160-2162
  10. Zhao F, Liu G, Wu J, Cao B, Tao X, He L, et al. Surveillance of macrolide-resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012. Antimicrob Agents Chemother. 2013; 57(3):1521–3
  11. Matsuoka M, Narita M, Okazaki N et al. Characterization and molecular analysis of macrolide-resistant mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicrob Agents Chemother 2004; 48:4624-4630
  12. Morozumi M, Iwata S, Hasegawa K et al. Acute respiratory diseases study group. Increased macrolide resistance of mycoplasma pneumoniae in pediatric patients with community acquired pneumonia. Antimicrob Agents Chemother 2008; 52:348-350
  13. R. Dumke, H von Baum et al. Occurrence of macrolide-resistant Mycoplasma pneumoniae strains in Germany. Clin Microbiol Infect 2010; 16:613-616
  14. Chironna M, Sallustio A, Esposito S, Perulli M, Chinellato I, Di Bari C, et al. Emergence of macrolide-resistant strains during an outbreak of Mycoplasma pneumoniae infections in children. J Antimicrob Chemother. 2011; 66(4):734-7
  15. Sauteur M Meyer Patrick, Bleisch Barbara et al. Swiss Med Wkly 2014
  16. Lung C David et al. Rapid Defervescence after Doxycycline Treatment of Macrolide-Resistant Mycoplasma pneumoniae Associated Community-Acquired Pneumonia in Children. Ped Infec Dis J 2013; vol 32:12:1396-1399
  17. Esposito S, Cohen R, Domingo JD et al. Antibiotic therapy for pediatric community-acquired pneumonia: do we know when, what and for how long to treat? Pediatr Infect Dis J 2012; 31: e78 – 85
  18. Principi N, Esposito S. Emerging role of Mycoplasma pneumoniae and Chlamydia pneumoniae in paediatric respiratory-tract infections. Lancet Infect Dis 2001; 1:334 – 44
  19. AliReza E et al. Macrolide- Resistant Mycoplasma pneumoniae in Humans, Ontario, Canada, 2010–2011. Emerg Infect Dis 2013; vol 19:9
  20. N. Miyashita, Y Kawai et al. Macrolide-resistant Mycoplasma pneumoniae in adolescents and community-acquired pneumonia. BMC Infect Dis 2012; 12:126
  21. Morozumi M, Ito A, Murayama Somay Y et al Assessment of real-time PCR for diagnosis of Mycoplasma pneumoniae pneumonia in pediatric patients. Canadian Journal of Microbiology 2006; 52, 2
22. Peuchant O, Ménard A et al. Increased macrolide resistance of Mycoplasma pneumonia in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J Antimicrob Chemother 2009 52-58